Detalhe da pesquisa
1.
Iodine and fertility: do we know enough?
Hum Reprod
; 36(2): 265-274, 2021 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33289034
2.
An observational study of pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists.
Aust N Z J Obstet Gynaecol
; 60(3): 405-411, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31583693
3.
Adverse skeletal effects of drugs - beyond Glucocorticoids.
Clin Endocrinol (Oxf)
; 82(1): 12-22, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25039381
4.
The impact of prolonged, maternal iodine exposure in early gestation on neonatal thyroid function.
Front Endocrinol (Lausanne)
; 14: 1080330, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36798662
5.
Treatment of infertility with hypogonadotropic hypogonadism: 10-year experience in Auckland, New Zealand.
Aust N Z J Obstet Gynaecol
; 52(3): 293-8, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22694078
6.
The SELFI Study: Iodine Excess and Thyroid Dysfunction in Women Undergoing Oil-Soluble Contrast Hysterosalpingography.
J Clin Endocrinol Metab
; 107(12): 3252-3260, 2022 11 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36124847
7.
Hysterosalpingography with Oil-Soluble Contrast Medium Does Not Increase Newborn Hypothyroidism.
Int J Endocrinol
; 2022: 4532714, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35242184
8.
Imatinib mesylate does not increase bone volume in vivo.
Calcif Tissue Int
; 88(1): 16-22, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20978751
9.
Evidence for a role for the p110-alpha isoform of PI3K in skeletal function.
Biochem Biophys Res Commun
; 391(1): 564-9, 2010 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19931507
10.
Response to Letter to the Editor From Marin et al: "The SELFI Study: Iodine Excess and Thyroid Dysfunction in Women Undergoing Oil-Soluble Contrast Hysterosalpingography".
J Clin Endocrinol Metab
; 108(9): e902-e903, 2023 08 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36948881
11.
Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.
J Bone Miner Res
; 22(11): 1679-89, 2007 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17663639
12.
Tyrosine Kinase Inhibitors Regulate OPG through Inhibition of PDGFRß.
PLoS One
; 11(10): e0164727, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27737004
13.
Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism.
N Engl J Med
; 355(23): 2494-5, 2006 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-17151376
14.
The skeletal effects of the tyrosine kinase inhibitor nilotinib.
Bone
; 49(2): 281-9, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21550432
15.
Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib.
J Clin Endocrinol Metab
; 94(4): 1131-6, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19174494
16.
Bone metabolism during long-term treatment with imatinib.
Leuk Lymphoma
; 54(8): 1783-5, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23278638